Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Pancreatic Cancer
Interventions
DRUG

Bevacizumab

5 mg/kg IV Over 90 Minutes Every 2 Weeks

DRUG

Erlotinib

100 mg by mouth Once Daily on days with radiation.

DRUG

Capecitabine

400 mg/m\^2 PO Twice Daily on days with radiation.

RADIATION

Radiation Therapy

Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00614653 - Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter